Article
Author: Fabre, Naomi ; Bai, Xinyu ; Bayerl, Felix ; Cronin, Shona M ; Nguyen, Trung Viet ; Schönlein, Martin ; Novatchkova, Maria ; Lauss, Martin ; Laniti, Denarda Dangaj ; Krecioch, Izabela ; Pottendorfer, Elisabeth ; Bayerl, Jonas ; Rieser, Sarah ; Wiesner, Thomas ; Coukos, George ; Castillon, Leticia ; Andreatta, Francesco ; Quek, Camelia ; Böttcher, Jan P ; Barras, David ; Obenauf, Anna C ; Vulin, Milica ; Muñoz I Ordoño, Miquel ; Estivill, Guillem ; Vanharanta, Sakari ; Zuber, Johannes ; Jönsson, Göran ; Hoffmann-Haas, Lisa ; Holstein, Felix ; Elewaut, Anais ; Pedde, Anna-Marie
AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3–7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3–5,8–10, the underlying cellular players and molecular mechanisms remain incompletely understood. Here we show that inflammatory monocytes can adopt a pivotal role in intratumoral T cell stimulation. These cells express Cxcl9, Cxcl10 and Il15, but in contrast to type 1 conventional dendritic cells, which cross-present antigens, inflammatory monocytes obtain and present peptide–major histocompatibility complex class I complexes from tumour cells through ‘cross-dressing’. Hyperactivation of MAPK signalling in cancer cells hampers this process by coordinately blunting the production of type I interferon (IFN-I) cytokines and inducing the secretion of prostaglandin E2 (PGE2), which impairs the inflammatory monocyte state and intratumoral T cell stimulation. Enhancing IFN-I cytokine production and blocking PGE2 secretion restores this process and re-sensitizes tumours to T cell-mediated immunity. Together, our work uncovers a central role of inflammatory monocytes in intratumoral T cell stimulation, elucidates how oncogenic signalling disrupts T cell responses through counter-regulation of PGE2 and IFN-I, and proposes rational combination therapies to enhance immunotherapies.